Clinical Trial Update: Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Long-term safety follow-up study of haematopoietic stem cell gene therapy for Wiskott-Aldrich Syndrome, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wiskott-aldrich Syndrome

Snippet

Sponsor: Genethon | Conditions: Wiskott-Aldrich Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING